81 citations
,
February 2019 in “Experimental & Molecular Medicine” PAK4 is crucial in cancer progression, brain development, and could be a therapeutic target, especially through the PAK4-CREB axis.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
55 citations
,
April 2010 in “Cancer and Metastasis Reviews” TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.
39 citations
,
May 2004 in “Clinics in Dermatology” The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.
35 citations
,
August 2021 in “npj Regenerative Medicine” Fibroblasts, cells usually linked to tissue repair, also help regenerate various organs and their ability decreases with age. Turning adult fibroblasts back to a younger state could be a new treatment approach.
30 citations
,
May 2019 in “Scientific Reports” Late pregnancy helps repair brain damage in rats due to the GABAergic system.
29 citations
,
May 2020 in “npj Regenerative Medicine” Immune cells help regulate hair growth, and better understanding this can improve hair loss treatments.
24 citations
,
March 2018 in “Experimental Dermatology” Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.
2 citations
,
May 2025 in “Infection” Awareness and better treatment of Demodex mites can improve health and quality of life.
2 citations
,
January 2025 in “Cutis” Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.
1 citations
,
December 2022 in “Biomolecules & therapeutics” Minoxidil may help reduce aging effects in brain cells.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
March 2026 in “European journal of ecology, biology and agriculture.” Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.
January 2026 in “Dermatology and Therapy” Poor sleep may lead to hair loss, and hair loss may affect sleep.
Understanding hair follicle signaling can improve hair disorder treatments.
January 2026 in “International Journal of All Research Education & Scientific Methods” Alopecia is caused by various factors, and new treatments like gene editing and regenerative medicine offer hope for personalized hair regrowth solutions.
December 2025 in “Journal of Composites and Compounds” Composite biomaterials can precisely control immune responses for better disease treatment.
Baricitinib effectively regrows hair in severe alopecia areata cases.
August 2025 in “Frontiers in Immunology” Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.
January 2024 in “International journal of homoeopathic sciences” Early intervention and patient education are crucial for managing alopecia areata.
December 2023 in “International journal of multidisciplinary research and analysis” SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.
April 2021 in “Sohag Medical Journal” Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.
April 2019 in “Journal of Investigative Dermatology” Differences in growth factors in platelet-rich plasma therapy for hair loss can vary between patients and can be influenced by the devices used, possibly leading to inconsistent results.
June 2018 in “Journal of Dermatological Science” UV radiation may cause DNA changes in skin, certain UVB therapy helps psoriasis, a new gene mutation is linked to mild piebaldism, different immune cells affect psoriasis, a drug promotes hair growth, and some cancer drugs could treat skin barrier issues.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
June 2022 in “COJ Biomedical Science & Research” PCOS management includes lifestyle changes and medications to improve fertility.
Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.
January 2019 in “ISGE series” The document concludes that effectively managing PCOS requires a multifaceted approach.
March 2018 in “Suez Canal University Medical Journal” NKG2D gene polymorphism doesn't affect SLE risk but may influence symptoms like rash and hair loss.